APM
ALXN

Avidity Partners Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Avidity Partners Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-507,700
Closed -$57M – 97
2020
Q2 		$57M Buy
507,700
+347,700
+217% +$36.9M 3.65% 7
2020
Q1 		$14.4M Buy
+160,000
New +$15.7M 1.99% 20

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's ALXN Position: Q3 2020 in Review

Avidity Partners Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 507,700 shares — an estimated $57M sold.

Avidity Partners Management first reported a position in ALXN in Q1 2020 and held it in 2 quarters. The position peaked at $57M in Q2 2020. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Avidity Partners Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Avidity Partners Management sold 507,700 Alexion Pharmaceuticals shares in Q3 2020, an estimated $57M.
  • Avidity Partners Management first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Avidity Partners Management's Alexion Pharmaceuticals position peaked at $57M in Q2 2020.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.